MX2024012348A - Forma cristalina de lanifibranor - Google Patents

Forma cristalina de lanifibranor

Info

Publication number
MX2024012348A
MX2024012348A MX2024012348A MX2024012348A MX2024012348A MX 2024012348 A MX2024012348 A MX 2024012348A MX 2024012348 A MX2024012348 A MX 2024012348A MX 2024012348 A MX2024012348 A MX 2024012348A MX 2024012348 A MX2024012348 A MX 2024012348A
Authority
MX
Mexico
Prior art keywords
lanifibranor
crystalline form
relates
ray diffraction
present
Prior art date
Application number
MX2024012348A
Other languages
English (en)
Spanish (es)
Inventor
Frédéric Bell
Benaissa Boubia
Original Assignee
Inventiva
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inventiva filed Critical Inventiva
Publication of MX2024012348A publication Critical patent/MX2024012348A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
MX2024012348A 2022-04-05 2024-10-04 Forma cristalina de lanifibranor MX2024012348A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22305456 2022-04-05
PCT/EP2023/058743 WO2023194339A1 (en) 2022-04-05 2023-04-04 Crystalline form of lanifibranor

Publications (1)

Publication Number Publication Date
MX2024012348A true MX2024012348A (es) 2024-11-08

Family

ID=81326293

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024012348A MX2024012348A (es) 2022-04-05 2024-10-04 Forma cristalina de lanifibranor

Country Status (14)

Country Link
US (1) US20250243192A1 (cg-RX-API-DMAC7.html)
EP (1) EP4504725A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025511847A (cg-RX-API-DMAC7.html)
KR (1) KR20250002337A (cg-RX-API-DMAC7.html)
CN (1) CN119301120A (cg-RX-API-DMAC7.html)
AR (1) AR128985A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023250118A1 (cg-RX-API-DMAC7.html)
CA (1) CA3247273A1 (cg-RX-API-DMAC7.html)
IL (1) IL316075A (cg-RX-API-DMAC7.html)
MX (1) MX2024012348A (cg-RX-API-DMAC7.html)
PY (1) PY2324870A (cg-RX-API-DMAC7.html)
TW (1) TW202404966A (cg-RX-API-DMAC7.html)
UY (1) UY40216A (cg-RX-API-DMAC7.html)
WO (1) WO2023194339A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022325334A1 (en) * 2021-08-12 2024-02-22 Inventiva Crystal form of lanifibranor, preparation method therefor, and use thereof
JP2026501899A (ja) 2023-01-19 2026-01-16 インベンティバ ラニフィブラノール製剤
WO2024251730A1 (en) 2023-06-05 2024-12-12 Inventiva Lanifibranor for use in the treatment of splanchnic vasodilatation in a patient with a liver condition
AR133887A1 (es) * 2023-09-22 2025-11-12 Inventiva Método de fabricación de lanifibranor
IL330214A (en) 2023-12-21 2026-08-01 Inventiva Combination therapy for the prevention and/or treatment of liver disease
AU2024409290A1 (en) 2023-12-21 2026-08-06 Inventiva Combination therapy for the prevention and/or the treatment of a liver disease
WO2025191292A1 (en) 2024-03-15 2025-09-18 Inventiva Methods and monitoring of treatment with lanifibranor
WO2025191117A1 (en) 2024-03-15 2025-09-18 Inventiva Prevention of blood disorders in patient treated with a ppar agonist
TW202604485A (zh) 2024-05-17 2026-02-01 法商因文帝華公司 患有肝損傷患者肝疾病之治療
WO2026115290A1 (en) 2024-11-28 2026-06-04 Inventiva Non-invasive monitoring of nash treatment with lanifibranor
WO2026125286A1 (en) 2024-12-09 2026-06-18 Inventiva Combinations comprising lanifibranor and a glp-1/gip/glucagon triple receptor agonist for use in the treatment of liver diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2890071B1 (fr) 2005-08-30 2007-11-09 Fournier Sa Sa Lab Nouveaux composes de l'indole
WO2022122014A1 (zh) 2020-12-11 2022-06-16 苏州科睿思制药有限公司 Lanifibranor的晶型及其制备方法和用途
WO2022143479A1 (zh) 2020-12-29 2022-07-07 广东东阳光药业有限公司 一种化合物的固体形式及其制备方法和用途
US20240246949A1 (en) 2021-06-10 2024-07-25 Teva Pharmaceuticals International Gmbh Solid state forms of lanifibranor and process for preparation thereof
CN115466252A (zh) 2021-06-11 2022-12-13 上海希迈医药科技有限公司 一种Lanifibranor的晶型及其制备方法
AU2022325334A1 (en) 2021-08-12 2024-02-22 Inventiva Crystal form of lanifibranor, preparation method therefor, and use thereof

Also Published As

Publication number Publication date
JP2025511847A (ja) 2025-04-16
EP4504725A1 (en) 2025-02-12
WO2023194339A1 (en) 2023-10-12
TW202404966A (zh) 2024-02-01
UY40216A (es) 2023-10-31
CA3247273A1 (en) 2023-10-12
IL316075A (en) 2024-12-01
PY2324870A (es) 2023-10-27
CN119301120A (zh) 2025-01-10
US20250243192A1 (en) 2025-07-31
KR20250002337A (ko) 2025-01-07
AR128985A1 (es) 2024-07-03
AU2023250118A1 (en) 2024-10-17

Similar Documents

Publication Publication Date Title
UY40216A (es) Forma cristalina de lanifibranor
CL2025003801A1 (es) Forma cristalina de un compuesto derivado de 4’-etinil-2-fluoro-2’-desoxi-adenosina sustituido
BR112023022755A2 (pt) Composto cíclico possuindo efeito inibidor seletivo para kras, mas não para hras e nras
AR120479A1 (es) Método para fabricar una partícula
CO2022011862A2 (es) Proceso para la preparacion de compuestos de antranilamida artropodicida
IL297180A (en) Process for synthesizing sulfonated triaryl methane compounds
BR112023005850A2 (pt) Processo para purificação de pleuromutilinas
TWD244638S (zh) 光罩盒之部分
JP1821191S (ja) 自転車用錠
ES1320276Y (es) Maquina formadora de cajas
KR20240014288A (ko) 친환경적 재생원료를 이용한 의류 제조방법
JP1825612S (ja) 工具箱
JP1810711S (ja) 工具箱
JP1810767S (ja) 工具箱
JP1810766S (ja) 工具箱
NL1220C (nl) Verbetering eener werkwijze ter vervaardiging van waardepapier
FR456775A (fr) Perfectionnements aux bracelets extensibles
FR469278A (fr) Jeu de construction décorative
FR438614A (fr) Machine pour la fabrication de flans de caisses renforcés par des taquets et liés par des fils métalliques
FR435263A (fr) Cachets de cire détachés par unités
ES52637A1 (es) Un procedimiento par la fabricación de rocas artificiales.
ES55414A1 (es) Un clase de opacificantes para la fabricación de esmaltes blancos.
CH65132A (de) Verfahren zur Herstellung einer dem Chiolith 6NaF, 2Al2F6 gleichenden Doppelverbindung zwischen Fluornatrium und Fluoraluminium
FR497931A (fr) Cylindre étireur en large
CH69959A (de) Verfahren zur Herstellung einer hochwirksamen, wasserlöslichen Desinfektionsseife